FDA expands Pfizer vaccine鈥檚 booster authorization to include 16- and 17-year-olds; CDC recommends
The Food and Drug Administration today the widely anticipated expansion of Pfizer鈥檚 COVID-19 vaccine emergency use authorization to allow booster doses for 16- and 17-year-olds. The FDA said boosters for this age group should be administered at least six months following the completion of an initial two-dose regiment. Following FDA鈥檚 decision, the Centers for Disease Control and Prevention formally recommended boosters for this age group.
鈥淲e know that COVID-19 vaccines are safe and effective, and I strongly encourage adolescents ages 16 and 17 to get their booster if they are at least 6 months post their initial Pfizer vaccination series,鈥 said CDC Director Rochelle Walensky, M.D.
Related News Articles
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium鈥
Headline
The Food and Drug Administration July 10 approved Moderna鈥檚 Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that鈥
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational鈥
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention鈥
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England鈥
Headline
A study published April 8 by the Public Library of Science鈥檚 Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of鈥